Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 26.
doi: 10.1007/s00210-025-04613-x. Online ahead of print.

Combined dapagliflozin and pioglitazone therapy in diabetic nephropathy: no added benefit beyond monotherapy in inflammation and fibrosis

Cinakova A  1 , Vavrincova-Yaghi D  1 , Vavrinec P  1 , Krenek P  1 , Klimas J  1 , Kralova E  2
Affiliations

Combined dapagliflozin and pioglitazone therapy in diabetic nephropathy: no added benefit beyond monotherapy in inflammation and fibrosis

Cinakova A et al. Naunyn Schmiedebergs Arch Pharmacol. .

Abstract

Diabetic nephropathy (DN) is currently a leading cause of end-stage renal disease. Both dapagliflozin and pioglitazone have shown protective effects on organ damage in diabetes, even beyond their blood glucose-lowering properties. This study aimed to assess whether the simultaneous activation of PPARγ and inhibition of SGLT2 cotransporters provide additive protection against inflammation and fibrosis which are highly engaged in the progression of DN in experimental type 1 diabetes mellitus. Diabetes was induced in Wistar rats using streptozotocin (55 mg/kg, i.p.), and the animals received daily chow containing dapagliflozin (10 mg/kg), pioglitazone (12 mg/kg), or their combination. Six weeks after streptozotocin administration, molecular, histological and immunohistochemical analyses were performed in the excised kidneys. In the kidneys of diabetic rats, disruption of renal function markers was accompanied by increased macrophage infiltration and collagen deposition. Both pioglitazone and dapagliflozin decreased proinflammatory markers expression (IL1b, IL6, Cox2, Tnfα) and CD68-positive areas. Both monotherapies positively modulated Tgfβ, HGF and Agtr1 expression, leading to fibrosis reduction and morphological normalisation. Similarly to pioglitazone, the combined therapy reduced α-SMA-positive areas. Despite an additive antihypertensive effect, the combination maximally reached the effect of the monotherapies in other measured parameters. Overall, both dapagliflozin and pioglitazone are renoprotective in monotherapy, but their combination does not provide additional benefits in reducing inflammation, fibrosis or restoring kidney function.

Keywords: Dapagliflozin; Diabetic nephropathy; Fibrosis; Inflammation; Pioglitazone; Rat.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: Experimental procedures were performed following the European animal research laws (European Communities Council Directive 2010/63/EU) and complied with the ARRIVE guidelines. The study protocol was approved by the Ethics Committee of the Faculty of Pharmacy at the Comenius University and by the State Veterinary and Food Administration of the Slovak Republic (protocol No: Ro-1636/17–221, 28 April 2017). All animals were handled by certified investigators and animal keepers. Competing interests: The authors declare no competing interests.

References

    1. Abdollahi E, Keyhanfar F, Delbandi A-A et al (2022) Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol 918:174715. https://doi.org/10.1016/j.ejphar.2021.174715 - DOI - PubMed
    1. Amano Y, Tsuchiya S, Imai M et al (2018) Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 497:207–213. https://doi.org/10.1016/j.bbrc.2018.02.055 - DOI - PubMed
    1. Braga Gomes K, Fontana Rodrigues K, Fernandes AP (2014) The role of transforming growth factor-beta in diabetic nephropathy. Int J Med Genet 2014:180270. https://doi.org/10.1155/2014/180270 - DOI
    1. Burns KD (2000) Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 36:449–467. https://doi.org/10.1053/ajkd.2000.16192 - DOI - PubMed
    1. Cai A, Shen J, Yang X et al (2023) Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels. Front Immunol 14:1205834. https://doi.org/10.3389/fimmu.2023.1205834 - DOI - PubMed - PMC